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The protective effects of pharmacological 
inhibitors of xanthine oxidoreductase (XOR) have 
implicated XOR in many inflammatory diseases. 
Nonetheless, the role played by XOR during 
inflammation is poorly understood. We previously 
observed that inhibition of XOR within the 
inflammatory mononuclear phagocytes (MNP) 
prevented neutrophil recruitment during adoptive 
transfer demonstrating the role of XOR in MNP 
mediated neutrophil recruitment. To further 
explore the role of XOR in the inflammatory state 
of MNP, we studied MNP isolated from 
inflammatory lungs combined with analyses of 
MNP cell lines. We demonstrated that XOR 
activity was increased in inflammatory MNP 
following insufflation of Th-1 cytokines in vivo 
and that activity was specifically increased by 
MNP differentiation. Inhibition of XOR reduced 
levels of CINC-1 secreted by MNP. Expression of 
PPARγ in purified rat lung MNP and MNP cell 
lines reflected both the presence of PPARγ iso-
forms and PPARγ SUMOylation, and XOR 
inhibitors increased levels of SUMO-PPARγ in 
MNP cell lines. Both ectopic overexpression of 
XOR cDNA and uric acid supplementation 
reduced SUMO-PPARγ in MNP cells. Levels of 
the M2 markers CD36, CD206, and Arginase-1 
were modulated by uric acid and oxonic acid, 
while siRNA to Sumo-1 or PIAS-1 also reduced 
Arginase-1 in RAW264.7 cells. We also observed 
that HIF-1α was increased by XOR inhibitors in 
inflammatory MNP and in MNP cell lines. These 
data demonstrate that XOR promotes the 
inflammatory state of MNP through effects on 
chemokine expression, PPARγ SUMOylation, and 
HIF-1α and suggest that strategies for inhibiting 
XOR may be valuable in modulating lung 
inflammatory disorders. 
 
The protective effects of the pharmacological 
inhibitors of xanthine oxidoreductase (XOR), 
allopurinol and oxypurinol, have implicated XOR in 
a wide range of human inflammatory diseases and in 
animal models of inflammatory disease. Injury from 
inflammatory bowel disease (IBD) and the related 
Crohn’s disease are reduced by XOR inhibitors (1,2); 
acute pancreatitis (3), lens induced uveitis (4), 
atherosclerosis (5), chronic heart failure (6,7), 
essential hypertension (8,9), and diabetic vascular 
injury (10-12) also exhibit inflammatory components 
that show improved function by treatment with XOR 
inhibitors. In the lung, inhibition of XOR is 
protective in chronic obstructive pulmonary disease 
airways (COPD) (13), ischemia reperfusion injury 
(14),  acute lung injury (15,16), and other respiratory 
disorders that exhibit an inflammatory component 
(17). Significantly, microarray analysis identified 
XOR as a prominent molecular signature of sepsis 
induced systemic inflammation in many organs, 
including the lung (18). These diverse observations 
suggest that XOR may play a fundamental role in 
inflammation and inflammatory diseases. 
While many cells of the tissue 
microenvironment, including vascular endothelial 
cells, tissue epithelial cells, leukocytes, or 
lymphocytes may be involved in the inflammatory 
response, mononuclear phagocytes (MNP) of the 
innate immune system play decisive roles in many 
inflammatory states. The MNP system includes 
lineage committed bone marrow precursors, 
macrophages, their monocyte precursors, and cells 
that are derived from this lineage including 
inflammatory and resident monocytes and 
macrophages found in the lung (19). In the lung, 
MNP and the MNP chemokine, MCP-1, contribute to 
the inflammation associated with COPD (20), and 
MNP and MCP-1 are involved in the pathogenesis of 
ventilator induced lung injury, acute lung injury, and 
the adult respiratory distress syndrome (ARDS) (21-
26).  
The contribution of MNP to inflammatory 
disorders is complex and not fully understood. 
Following the induction of inflammation in the lung, 
monocytes are recruited into the airspace where they 
rapidly differentiate into macrophages (27-29). Once 
established in the airspace MNP produce many pro-
inflammatory mediators that contribute to 
inflammation and injury (15,21,24-26,30,31). MNP 
also respond to diverse activating signals in the 
inflammatory environment. Classically activated 
(M1) MNP are defined by their response to the 
bacterial lipopolysaccharide (LPS) and to the T 
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helper-1 (Th-1) cytokines IL-1 and/or IFN- and may 
contribute to the ensuing inflammation (32-35). On 
the other hand, alternatively activated (M2) MNP are 
defined by their response to interleukins-4 and 13 
(IL-4, -13) and may exhibit anti-inflammatory 
properties that contribute to pathogen clearance and 
tissue repair (19,36). 
Significantly, XOR has been found to 
comprise an essential component of innate immunity 
(37), to regulate leukocyte adhesion in vivo (38-40), 
and as a product of the MNP itself contribute to 
cytokine induced acute lung injury (15). Inhibition of 
XOR within the newly recruited inflammatory MNP 
prevented neutrophil (polymorphonuclear phagocytes 
or PMN) recruitment during adoptive transfer 
demonstrating a key role for XOR in MNP mediated 
PMN recruitment (15). Nonetheless, the role played 
XOR in MNP during inflammation is still poorly 
understood, and in the present experiments we 
hypothesized that XOR may regulate basic MNP 
functions that contribute to inflammation. Data 
shown here demonstrate that XOR promotes the 
inflammatory state of MNP in part through effects on 
chemokine expression, PPARγ sumoylation, and 
HIF-1α. 
 
EXPERIMENTAL PROCEDURES 
 
Reagents - Most reagents, buffers, substrates, 
and inhibitors were purchased from Sigma Chemical 
Company (St. Louis MO, USA). Recombinant 
human interleukin-1-β (IL-1; 201-LB), interferon- 
(IFN-; 285-IF-100), and recombinant human MCP-1 
(279-MC) were purchased from RD Systems 
(Minneapolis, MN). Sterile normal saline (0.9% 
NaCl, pH 6.0) was purchased from Baxter Health 
Care (Deerfield, Ill). Phorbol 12-myristate 13-acetate 
(PMA) was from Sigma (P8139). E. coli 
lipopolysaccharide (LPS) was from Sigma (L2880). 
MIG132 (Z-Leu-Leu-Leu-al) was purchased from 
Sigma (C2211) and prepared in DMSO as indicated 
by the supplier. Allopurinol (A8003) and oxypurinol 
(O6881) were from Sigma. Vitamin D3 (Hoffman-La 
Roche, Nutley, NJ) was prepared in 100% ethanol. 
TGFβ1 (240-B) was purchased from R&D Systems . 
All-trans-retinoic acid (ATRA) was purchased from 
Sigma. The XOR inhibitor Y-700 was obtained from 
Dr. Atsushi Fukunari at Mitsubishi Pharma 
Corporation (Chiba, Japan) and prepared in sodium 
pyrophosphate as described (41). Rabbit polyclonal 
anti-PPARγ antibody (H-100; sc-7196), rabbit 
polyclonal anti-Arginase-1 (H-51; sc-20150), and 
rabbit polyclonal anti-GAPDH antibody (sc25778) 
were from Santa Cruz Biotechnology (Santa Cruz, 
CA). Mouse monoclonal anti-HIF-1α antibody 
(NB100-123) was from Novus Biologicals (Littleton, 
CO). Rabbit monoclonal anti-SUMO-1 (ab32058) 
was from Abcam, Inc. (Cambridge, MA). Goat anti 
mouse IgG-HRP antibody (sc-2005) and goat anti 
rabbit IgG-HRP antibody (sc-2004) were purchased 
from Santa Cruz.  The Immobilon Chemiluminescent 
horseradish peroxidase (HRP) detection kit 
(WBKLS0100) was from Millipore Corporation 
(Billerica, MA). FITC anti-mouse CD206 (123005) 
was from BioLegend ( San Diego, CA.) and PE anti-
mouse CD36 (12-0361) was from eBioscience (San 
Diego, CA.). Anti-SUMO-1 siRNA (sc-36574) and 
anti-PIAS-1 siRNA (sc-36220) were from Santa Cruz 
Biotechnology.  
Animal Manipulations - Healthy male 
Sprague-Dawley rats (250-350g body weight, Sasco, 
Omaha, NE) were used in all studies. The Th-1 
cytokines, 50 ng of recombinant rat IL-1β and 100 ng 
of IFN-  in 0.5 mls of normal saline, were delivered 
intratracheally into the airway of rats previously 
anesthetized with ketamine/xylazine and lung tissues 
were harvested 5 or 24 hours later as described (15). 
Control rats were insufflated with normal saline 
alone. The use of rats in this study was approved by 
the University of Colorado Animal Care and Use 
Committee under the protocol number 
21901907(08)1F. 
Purification of MNP - Resident alveolar 
macrophages (RAM) were purified from the lungs of 
control rats by lavage as described (15). Circulating 
monocytes (CM) were purified from whole blood of 
control rats on percoll gradients (15). Alveolar MNP 
(A-MNP) comprising both the resident AM 
population and the newly recruited MNP were 
purified by lavage from lungs of rats insufflated with 
Th-1 cytokines 5 or 24 hours before. Cells were 
washed in RPMI medium and were then plated into 
flasks with RPMI medium and allowed to adhere for 
1 hr.  Non-adherent cells were removed, and the 
remaining, adherent cells were washed 4 times with 
PBS and harvested from the plates by scraping into 
PBS/EDTA (42). Interstitial MNP present in the lung 
tissue (I-MNP) were purified from the lungs of rats 
following removal of the A-MNP and therefore do 
not contain the resident AM population. Lungs were 
lavaged to obtain the A-MNP population, perfused 
blood free, and cells not released by lavage were 
prepared as described (43).  Lung tissues were 
incubated under moderate agitation for 60 min in 
RPMI media containing 100 UmL-1 Collagenase 
Type 1 and 50 UmL-1 DNAse at 37oC.  After 
incubation, the digested tissue was passed through a 
sterile sieve to remove tissue fragments, and the cells 
obtained in the flow through were adhered to flasks 
as described above. Adherent cells were suspended in 
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saline to a final concentration of 2 x 106 cells ml-1. 
MNP comprised >95% of the cells recovered from 
adhesion as determined by microscopic examination 
of Wright’s stained cells and M-CSF induced 
differentiation from both the A-MNP and the I-MNP 
preparations (15).  
Cell Culture - Human U-937 cells (ATCC 
number CRL-1593.2), THP-1 cells (ATCC number 
TIB-202), and HL60 cells (University of Colorado 
Cancer Center, UCD, Aurora, CO) were grown in 
RPMI 1640 medium with 10% fetal bovine serum 
and 1X anti-biotic/anti-mycotic cocktail (GIBCO) at 
pH 7.4 and 37oC as indicated by the supplier. Cells 
were seeded in 12 well plates at 1 x 106 cells well-1. 
NR8383 normal rat lung alveolar macrophage cell 
line was obtained from ATCC (CRL-2192) and 
grown exactly as specified by the supplier. The 
adherent RAW264.7 mouse monocyte/macrophage 
cell line was obtained from ATCC (TIB-71) and 
grown in DMEM with 10% fetal bovine serum and 
1X anti-biotic/anti-mycotic cocktail (GIBCO) at pH 
7.4 and 37oC as indicated by the supplier.  
SDS-PAGE and Western Immunoblot 
Analysis - Whole cell lysates were either prepared as 
described previously (15) and the protein 
concentration determined by using the bicinchoninic 
acid assay (Sigma) or cells were disrupted in 2X 
Laemmli Sample Buffer (Bio-Rad Laboratories, Inc., 
Hercules, CA; #161-0737), sonicated on ice twice for 
15 seconds, and protein concentration determined 
using Pierce 660nm protein assay (Thermo Scientific, 
Rockford, IL). Aliquots containing 50 μg of protein 
were incubated with equal amounts of loading buffer 
(5% β-mercaptoethanol, 95% Laemmli loading 
buffer) for 10 mins at 37˚, then boiled for 5 minutes. 
Samples were then separated by electrophoresis on 
7.5% SDS-PAGE or 4% to 15% gradient SDS-PAGE 
gels for 40 min at 100 V, transferred to PVDF 
membranes (Whatman, Inc, Albama, USA). 
Membranes were blocked overnight at 4° in 5% non-
fat dried milk in Tris-buffered saline (pH 7.6) 
containing 0.1% Tween 20. Membranes were then 
incubated with antibodies as indicated.  Antigen-
antibody complexes were detected by reaction with a 
chemiluminescent HRP Western blotting detection 
kit according to manufacturer’s instruction (Millipore 
Corporation). Experiments were run in triplicate 
unless otherwise indicated, and representative 
immunoblots are shown. Band intensities were 
quantitated by scanning dosimetry with ImageQuant 
software. 
Chemokine Quantitation – CINC-1, MCP-1, 
IL-10, and VEGF were determined either by ELISA 
(Enzyme-Linked ImmunoSorbent Assay) using kits 
from R&D Systems Inc. (CINC-1, RCN100) or by 
multiplex bead analysis using the Milliplex Rat 
Cytokine Kit from Millipore Corp. (Billerica, MA) 
(MCP-1, IL-10, VEGF). Data were quantitated on a 
Luminex 100 reader according to the manufacturer’s 
instructions. VEGF was also measured using the rat 
specific Proteome Profiler Array (# ARY008, R&D 
Systems, Inc.). 
Flow Cytometry - RAW 264.7 cells were 
grown as indicated, shifted into growth medium 
containing charcoal stripped and heat inactivated 
FBS and treated with 10 ng/ml IL-4 one hour after 
exposure to oxonic acid and/or uric acid at the 
indicated doses. Cells were harvested 24 hrs after 
treatment. Treated cells were collected into FACS 
running buffer (PBS with 2 mM EDTA and 0.5% 
BSA), washed twice in PBS, and were then fixed in 
4% paraformaldehyde for 10 minutes. Cells were 
stained with anti-CD206 (50ng/105 cells) and anti-
CD36 (2ng/105cells) fluorescently-conjugated 
primary antibodies in 200 ul running buffer for 20 
minutes on ice. Samples were washed and data 
acquired on a MACSQuant flow cytometer (Miltenyi 
Biotec). 
 XOR Quantitation - Total XOR activity was 
determined at 293nm by quantitation of oxypurinol 
inhibitable uric acid synthesis using a Beckman-
Coulter DU640 spectrometer, 1cm path length, and a 
molar extinction coefficient for uric acid of 12,600M-
1 as previously described (44). All XOR activity data 
show nMol of Uric Acid/min/mg of total protein. 
Statistical Analyses - Data are expressed as 
the mean and standard error of the mean and were 
assessed for significance using the Student’s t-test or 
ANOVA. A p value of <0.05 was considered 
significant.  
 
RESULTS 
 
  XOR Activity is Increased in A-MNP and I-
MNP Following Insufflation of Th-1 Cytokines In 
vivo - XOR activity is rapidly increased in MNP 
purified from the bronchoalveolar lavage (BAL) of 
rats insufflated with the Th-1 cytokines IL-1β and 
IFNγ (15). In the present work, we found extremely 
low levels of XOR activity in resident alveolar 
macrophages (RAM) prior to cytokine insufflation, 
and undetectable levels in circulating monocytes 
(CM) from the same rats (Fig. 1A). In contrast, both 
alveolar MNP (A-MNP) and interstitial MNP (I-
MNP) purified from rat lungs 24 hrs after Th-1 
cytokine insufflation exhibited high levels of XOR 
activity (Fig. 1A).  
Since MNP XOR activity was increased in 
both A-MNP and I-MNP populations, and was 
detected previously as early as 4 hrs following 
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cytokine insufflation, we hypothesized that XOR 
activity may be stimulated either by MNP 
differentiation per se or by exposure of RAM cells to 
Th-1 cytokines. To determine if XOR activity was 
increased in RAM cells by Th-1 cytokines, RAM 
cells were purified from the lungs of native, untreated 
rats and exposed to Th-1 cytokines in vitro for 24 hrs. 
In addition, XOR activity was measured in Th-1 
cytokine stimulated normal rat alveolar macrophage 
cell line NR8383. The NR8383 cell line was derived 
from the rat RAM cell population and has been 
reported to exhibit many characteristics of normal 
RAM cells (45). We observed approximately 10 fold 
lower stimulation of XOR activity in RAM cells by 
the Th-1 cytokines IL-1β, IFNγ, IL-1β/IFNγ, or LPS 
(Fig. 1B; Table 1) than was observed in A-MNP or I-
MNP from cytokine insufflated rats. Furthermore, 
Th-1 cytokine stimulation of NR8383 also exhibited 
approximately 10 fold lower stimulation of XOR 
activity than in A-MNP or I-MNP (Fig. 1C, Table 1).  
XOR Activity is Increased by MNP 
Differentiation In vitro - To determine if XOR 
activity was increased by differentiation of MNP per 
se, we examined the effect on XOR of differentiation 
induced in U937 human myeloid cells in vitro. 
Unlike RAM that are fully differentiated 
macrophages, U937 cells exhibit monocyte-like 
characteristics and differentiate into macrophages by 
treatment with PMA or vitaminD3/TGFβ (46). 
Exposure to all trans retinoic acid (ATRA) promotes 
differentiation along the granulocytic lineage (47). In 
addition, since exposure of circulating monocytes to 
the chemokine MCP-1 is an early event in 
recruitment to an inflammatory site that may be 
involved in differentiation along the MNP lineage 
(48,49), we treated U937 cells with MCP-1 as well. 
We observed that XOR activity was increased in 
U937 cells by treatment with PMA, D3/TGFβ, or 
MCP-1 but not by exposure to ATRA (Fig. 2A). 
Increased XOR activity in U937 cells following 
PMA or MCP-1 treatment was both dose and time 
dependent (Fig. 2B, C). Thus, induction of 
macrophage differentiation or exposure to the MNP 
chemokine MCP-1 in human U937 cells increases 
XOR activity.  These data demonstrate that XOR 
activity is increased in the inflammatory MNP by 
insufflation of Th-1 cytokines, and that 
differentiation per se and the MNP chemokine MCP-
1 may both contribute to the increased XOR activity 
observed in the inflammatory MNP. 
XOR Inhibition Reduces Levels of CINC-1 
Secreted by Inflammatory MNP - To determine if 
XOR contributes to the inflammatory state of MNP 
we quantitated levels of CINC-1 and MCP-1 in rats 
insufflated with Th-1 cytokines. We observed that 
levels of CINC-1 and MCP-1 were elevated in both 
the serum and cell free lavage five hours after 
insufflation of Th-1 cytokines compared to levels 
measured from saline insufflated sham control rats 
(Fig. 3A). Inflammatory MNP harvested from the 
lungs of Th-1 cytokine insufflated rats were 
cultivated in vitro, and levels of CINC-1, MCP-1, 
and IL-10 secreted into the culture medium were 
measured over the course of 48 hours in the presence 
or absence of LPS. LPS increased the secretion of 
CINC-1 and IL-10 from inflammatory MNP over the 
course of 48 hrs in vitro (Fig. 3B), but did not 
significantly change secretion of MCP-1. CINC-1 
secretion was inhibited by co-incubation with 
allopurinol or oxypurinol (Fig. 3C) even after 
exposure to LPS (Fig. 3D). No significant effect of 
allopurinol was observed on secretion of MCP-1 or 
IL-10.  These data demonstrate that XOR contributes 
to the secretion of the PMN chemokine CINC-1 by 
MNP, and that XOR inhibition reduces CINC-1 
secretion. 
Expression of PPARγ in Purified Rat Lung 
MNP and Cultured Myeloid Lineage Cells - 
Regulation of MNP differentiation along an 
inflammatory (M1) pathway or an anti-inflammatory 
(M2) pathway (19,36) is mediated in part by the 
Peroxisome Proliferator Activator Receptor-γ (50), 
with high PPARγ promoting the M2 state. We 
purified RAM from untreated control rat lungs and 
both A-MNP and I-MNP from rats treated with Th-1 
cytokines 24 hrs before. Western immunoblot of 
whole cell extracts revealed immunoreactive bands at 
50/55 KDa, 62/67 KDa, and 78 KDa that were 
reactive to the anti-PPARγ antibody (Fig. 4A). 
Immunoreactive bands at 50/55 KDa and 62/67 KDa 
were reduced in both A-MNP and I-MNP compared 
to the RAM. Immunoreactive bands at 50/55 KDa, 
62/67 KDa, and 78 KDa were all reduced by 
inclusion of purified recombinant PPARγ in the 
western immunoblot (data not shown). A similar 
pattern of immunoreactivity was obtained for several 
cultured myeloid lineage cells by reaction to the 
PPARγ antibody (Fig. 4B). Immunoreactive bands at 
50/55 KDa and 62/67 KDa were predominant, with 
little evidence of a 78 KDa band, in each of the 
cultured MNP cell lines examined. U937 and THP-1 
cells expressed similar levels of the bands at 50 and 
55 KDa. Treatment of RAW264.7 cells with IL-4 
resulted in marked increase in the immunoreactive 
band migrating at 62/67 KDa (Fig. 4C), suggesting 
that it may constitute a modified form of PPARγ 
induced by IL-4.  
The Pattern of PPARγ Immunoreactive 
Material Reflects Both the Presence of PPARγ Iso-
forms and PPARγ Sumoylation - PPARγ is encoded 
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by a single gene in rats, mice, and humans that yields 
a primary translation product of 505 amino acids and 
55  KDa in mass (51). Cleavage of 30 amino acids 
from the amino terminus of PPARγ2 (55 KDa) 
produces the PPARγ1 isoform (50 KDa). Our data 
indicate that U937 and THP-1 cells express both of 
these isoforms.  PPARγ is subject to post-
translational sumoylation at two sites in the primary 
translation product: at K107 in PPARγ2 and K77 in 
PPARγ1 and at  K395 in PPARγ2 and K365 in 
PPARγ1 (51). While multiple sumoylation events of 
PPARγ have been described that may contribute to 
the increased mass of PPARγ (51), a single 
sumoylation adduct can add 12 KDa to the mass (52). 
To determine if the immunoreactive bands at 62/67 
KDa reflect the presence of sumoylated PPARγ, we 
transfected RAW264.7 cells with anti-SUMO-1 
siRNA or siRNA for the PIAS SUMO-1 conjugating 
enzyme (52,53). Cells were then treated with either 
IL-4, PMA and oxypurinol, or PMA and Y-700 (as 
described in Figure 6). Western immunoblots were 
performed on WCE 24 hrs after treatment using 
antibodies to PPARγ (Fig. 5). Scanning dosimetry 
revealed that exposure to anti-SUMO-1 siRNA 
reduced the immunoreactive band at 62/67 KDa 
relative to the scrambled siRNA control by 50%, 
while exposure to anti-PIAS siRNA reduced the 
same band by 75% (Fig. 5A, C). Furthermore, 
exposure of RAW264.7 cells to anti-SUMO-1 siRNA 
followed by treatment with IL-4 decreased both the 
62/67 KDa immunoreactive band and decreased the 
free SUMO-1 band at 12 KDa (Fig. 5B). These data 
indicate that the anti-PPARγ immunoreactive band at 
62/67 KDa contains a SUMO-1 adduct. 
XOR Inhibitors Increase Levels of SUMO-
PPARγ in Cultured Myeloid Lineage Cell Lines - To 
determine the effect of XOR inhibition on PPARγ or 
SUMO-PPARγ (S-PPARγ) in myeloid lineage cell 
lines, we exposed human U937, THP-1, and HL60 
cells and the mouse RAW264.7 MNP cell line to the 
XOR inhibitors Y-700 or oxypurinol. After 1 hr cells 
were exposed to 30 nM PMA and 24 or 48 hrs later 
cell lysates were prepared. While western 
immunoblot analysis showed increases in PPARγ by 
PMA alone (Fig. 4B), we observed very little effect 
of PMA alone on SUMO-PPARγ in U937, THP-1, 
HL60, or RAW264.7 cells (Fig. 6). However, 24 hrs 
after treatment U937, THP-1, HL60, and RAW264.7 
cells showed marked increase in levels of SUMO-
PPARγ by both Y-700 and oxypurinol compared to 
control cells exposed to PMA alone. The increase in 
SUMO-PPARγ levels by XOR inhibitors occurred 
even in the absence of PMA stimulation. The 
increase in SUMO-PPARγ levels observed at 24 hrs 
in the presence of XOR inhibitors was frequently 
diminished by 48 hrs, although the basis for this 
effect is not presently understood.  
Both Ectopic Overexpression of XOR cDNA 
and Uric Acid Supplementation Reduce SUMO-
PPARγ in Stimulated Myeloid Lineage Cells - Further 
evidence that XOR was involved in modulating 
62/67 KDa SUMO-PPARγ was obtained in three 
ways. First, to determine if XOR overexpression 
would block IL-4 induced SUMO-PPARγ, 
RAW264.7 cells were transfected with pCMV-Myc-
XOR at various doses of input DNA. pCMV-Myc-
XOR is a cDNA expression vector containing a 
functional XOR cDNA that is expressed under the 
control of the CMV constitutive promoter and 
produces ectopic overexpression of XOR (54). We 
observed that ectopic overexpression of XOR dose 
dependently reduced levels of SUMO-PPARγ in IL-4 
treated RAW264.7 cells (Fig. 7A). Next, RAW264.7 
cells were treated with IL-4 in the presence or 
absence of uric acid, the immediate product of XOR 
catalysis. Uric acid dose dependently reduced IL-4 
stimulated SUMO-PPARγ at 62/67 KDa (Fig. 7B). 
Finally, U937 cells were exposed to PMA/Y-700 in 
the presence or absence of uric acid. Again, uric acid 
dose dependently reduced 62/67 KDa SUMO-PPARγ 
induced in U937 cells by PMA/Y-700 (Fig. 7C).  
Arginase-1 Levels Are Modulated by Uric 
Acid, Oxonic Acid,  and Anti-Sumo-1 or Anti-PIAS 
siRNA in RAW264.7 Cells - Induction of Arginase-1 
by IL-4 may be specifically mediated by sumoylation 
of PPARγ (36,55), and modulation of IL-4 induced 
PPARγ sumoylation by uric acid (shown here) 
specifically predicts that uric acid will inhibit IL-4 
induced Arginase-1. This prediction was tested in IL-
4 treated RAW264.7 cells. IL-4 was found to 
increase Arginase-1 levels in a dose dependent 
fashion to 20 ng/ml, the highest dose tested (Fig. 
8A). Transfection of RAW264.7 cells with anti-
SUMO-1 or anti-PIAS siRNA reduced both the 
levels of 62/67 KDa Sumo-PPARγ and Arginase-1 
(Fig. 8B), demonstrating that IL-4 induced Arginase-
1 was dependent on sumoylation. To determine if 
XOR overexpression would also block IL-4 induced 
Arginase-1, RAW264.7 cells were transfected with 
pCMV-Myc-XOR at various doses of input DNA and 
treated with IL-4 for 24 hrs. Ectopic overexpression 
of XOR cDNA dose-dependently reduced Arginase-1 
levels in IL-4 cells (Fig.8C). The effect of uric acid 
on IL-4 induced Arginase-1 was tested in two ways. 
In the first, the enzyme uricase that degrades uric 
acid to allantoin was inhibited with oxonic acid 
which then acts to elevate uric acid. Oxonic acid dose 
dependently inhibited IL-4 induced Arginase-1 (Fig. 
8D). In the second, uric acid was added exogenously 
to IL-4 treated RAW264.7 cells in the presence of 50 
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uM oxonic acid to block uric acid degradation. Uric 
acid dose dependently decreased levels of IL-4 
induced Arginase-1, an effect that was most 
pronounced at the higher doses of uric acid (Fig. 8E). 
These data demonstrate that ectopic overexpression 
of XOR or uric acid reduced levels of Arginase-1 
induced by IL-4 treatment through a sumoylation 
dependent process. 
The M2 markers CD36 and CD206 Are Also 
Modulated by Uric Acid and Oxonic Acid – CD36 
and CD206 are additional markers of the alternative 
(M2) state of macrophage activation (36). 
RAW264.7 cells were exposed to oxonic acid or to 
uric acid in the presence of oxonic acid and were 
then treated with IL-4. Cells were analyzed by FACS 
24 hrs later. As observed for levels of Arginase-1, 
both oxonic acid and uric acid dose dependently 
reduced levels of CD36 and CD206 detected by 
FACS (Fig. 8F).      
HIF-1α is Increased by XOR Inhibitors in 
Inflammatory MNP and in Cultured Myeloid Lineage 
Cells - The Hypoxia Inducible Factor -1α (HIF-1α) is 
a transcription factor mediating both glycolytic and 
hypoxic effects in leukocytes. HIF-1α is subject to 
sumoylation that may affect both its stability and its 
transcriptional activity (56,57). To determine if XOR 
also modulated levels of HIF-1α in inflammatory 
MNP, we examined levels of HIF-1α in I-MNP 
purified from Th-1 cytokine insufflated lungs by 
western immunoblot. HIF-1α was undetectable in I-
MNP immediately after isolation. However, HIF-1α 
levels in I-MNP showed both time and dose 
dependent accumulation when cells were treated in 
vitro with the proteosome inhibitor MIG132 (Fig. 
9A). MIG132 dependent accumulation of HIF-1α in 
I-MNP occurred during both normoxic (21% O2) and 
hypoxic (1% O2) culture in vitro (Fig. 9B). 
Concurrent treatment of I-MNP with MIG132 and 
three different inhibitors of XOR (allopurinol, 
oxypurinol, or Y-700) resulted in marked increase in 
HIF-1α levels over MIG132 treatment alone for cells 
cultured in either normoxia or hypoxia (Fig. 9B). 
These data suggest that XOR may exert a suppressive 
or modulating effect on levels of HIF-1α in I-MNP 
purified from Th-1 cytokine insufflated lungs. 
Furthermore, exposure of I-MNP to Th-1 cytokines 
IL-1β, IFNγ, or LPS showed increased levels of HIF-
1α in the presence of Y-700 that did not arise in the 
absence of Y-700 (Fig. 9C). 
 To determine if XOR exerted a similar 
modulating effect on HIF-1α in PMA differentiated 
U937 cells, U937 cells were differentiated with PMA 
and after 48 hrs treated with MIG132 and Th-1 
cytokines in the presence or absence of Y-700. We 
observed that HIF-1α was nearly undetectable in 
differentiated and normoxically grown U937 cells 
treated with Th-1 cytokines in the absence of Y-700, 
while concurrent treatment with Y-700 resulted in 
increased levels of HIF-1α (Fig. 9D). Growth of the 
same cells in hypoxia resulted in significantly higher 
levels of HIF-1α for cells grown in the presence of 
Y-700 (Fig. 9D). Thus, concurrent treatment of PMA 
differentiated U937 cells with Th-1 cytokines in the 
presence of the XOR inhibitor Y-700 resulted in 
increased levels of HIF-1α that were not observed in 
the absence of Y-700. These data suggest that XOR 
may also exert a modulating effect on HIF-1α levels 
in PMA differentiated and Th-1 cytokine treated 
U937 cells as well. 
 Vascular endothelial growth factor (VEGF) 
is an important target of HIF-1 regulation. We 
observed that I-MNP showed marked accumulation 
of VEGF when cultured in vitro in normoxia over the 
course of 48 hrs (Fig. 9E). Cells exposed to MIG132 
in the presence or absence of XOR inhibitors for 
either 6 or 24 hrs showed marked decrease in VEGF 
secretion. Since the profound suppression of VEGF 
by MIG132 may have obscured the effects of XOR 
inhibitors, cells were treated with Y-700 in the 
absence of MIG132 and secreted VEGF was 
measured in the cell free culture medium. Y-700 
alone markedly suppressed secretion of VEGF.  
 
DISCUSSION 
 
XOR plays a central role in the function of 
innate immunity and inflammation, and it is an 
important mediator of many inflammatory diseases in 
humans (37,58). XOR is upregulated in many 
inflammatory models (15,18) where it shows 
particularly high levels of activity in the 
inflammatory MNP. Inhibition of XOR specifically 
reduces PMN recruitment to an inflammatory site in 
vivo (15,59), and inhibition of XOR specifically in 
the MNP, but not the PMN, modulates subsequent 
PMN recruitment (15,60). Thus, XOR contributes to 
the development of inflammation as a product of the 
newly recruited inflammatory MNP. This 
observation is important because the MNP 
themselves contribute to injury of the lung epithelium 
and XOR inhibitors may provide critical support of 
the inflamed lung (15,21,22). Despite the vast 
amount of literature published on the role of XOR in 
inflammatory disease and the broadly protective role 
afforded by XOR inhibitors, surprisingly little is 
known about the mechanisms by which XOR 
contributes to inflammation. Data shown in the 
present report demonstrate that XOR is both 
activated by MNP differentiation and contributes to 
the inflammatory state of the MNP. XOR was found 
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to promote the inflammatory state of the MNP by 
contributing to inflammatory chemokine secretion, 
regulation of PPARγ sumoylation, and HIF-1α 
stability.  
XOR activity was markedly elevated in both 
A-MNP and I-MNP following insufflation of Th-1 
cytokines in contrast to the very low activity 
observed in CM or RAM from untreated control rats. 
While XOR activity was increased by treatment of 
RAM or NR8383 normal rat macrophages with Th-1 
cytokines, XOR activity failed to reach the levels 
observed in inflammatory MNP isolated from Th-1 
cytokine insufflated rats. Thus, exposure of RAM to 
Th-1 cytokines alone could not account for the level 
of XOR activity observed in the inflammatory MNP. 
Furthermore, XOR activity was increased by agents 
promoting macrophage, but not granulocyte, 
differentiation in U937 cells. Treatment with 
vitaminD3/TGFβ or PMA increased XOR activity to 
levels approaching those observed in MNP from Th-
1 cytokine insufflated rats. XOR activity was also 
increased by treatment with MCP-1, and this is 
important because MCP-1 is a central chemokine 
mediating the recruitment of monocytes to an 
inflammatory site including the lung (26,61) and may 
contribute to the inflammatory state of MNP 
(19,62,63). These data demonstrate XOR activity is 
markedly increased by agents promoting MNP 
differentiation along an inflammatory pathway. 
Evidence that XOR contributes to the 
inflammatory state of MNP was derived in several 
ways. Insufflation of Th-1 cytokines in rats produced 
a rapid rise in both serum and lavage chemokines for 
PMN (CINC-1) and MNP (MCP-1). Both CINC-1 
and MCP-1 were secreted by the MNP to a much 
greater extent than by the PMN isolated from the 
same rats (data not shown), and chemokine secretion 
was sustained after placing the MNP in culture. 
Significantly, CINC-1 levels were markedly elevated 
by treatment of the cultured MNP with LPS, and both 
uninduced and LPS induced CINC-1 was 
significantly reduced by co-incubation with XOR 
inhibitors. These data are consistent with and extend 
both our previous observations demonstrating that 
adoptive transfer of XOR inhibited MNP reduces 
PMN influx into the rat lung (15) and with data 
obtained in mice demonstrating the key role played 
by MNP in recruitment of PMN to the lung during 
inflammation (64-66). Consistent with the role of 
XOR in promoting the inflammatory state of MNP, 
we observed that the anti-inflammatory cytokine IL-
10 was not modulated by inhibition of XOR. 
Further evidence that XOR contributes to the 
inflammatory state of MNP was derived by analysis 
of PPARγ. PPARγ is a dual-function, ligand 
activated, member of the nuclear hormone receptor 
superfamily of transcription factors. Transcriptional 
activation by PPARγ requires both ligand binding 
and interaction with the retinoid X receptor (RXR). 
While transcriptional repression of inflammatory 
gene expression by PPARγ is well recognized, it is 
not yet fully understood (67,68). PPARγ expressed in 
the MNP plays an important role in regulating lung 
inflammation (69,70). RAM express high levels of 
PPARγ and this is down regulated by Th-1 cytokines 
(69). Down regulation of MNP PPARγ is associated 
with enhanced lung inflammation and injury (71-73), 
whereas activation or induction of MNP PPARγ is 
associated with an anti-inflammatory state 
characterized by reduced leukocyte infiltration, 
reduced inflammatory cytokine expression, and 
enhanced expression of anti-inflammatory cytokines 
(50,74-76). We observed an unexpectedly complex 
pattern of immunoreactive material on PPARγ 
western blots of freshly isolated rat MNP and from 
several cultured human and rodent MNP cells lines 
including U937, THP-1, HL-60, and RAW264.7 
cells. Freshly isolated MNP from the rat exhibited 
immunoreactive material at 78 KDa, 62/67 KDa, and 
50/55 KDa using an antibody to PPARγ, whereas we 
observed immunoreactive material predominantly at 
62/67 KDa and 50/55 KDa in the cultured cell lines. 
In rats, mice, and humans PPARγ is encoded by a 
single gene that yields a primary translation product 
of 505 amino acids and 55 KDa in mass (51), and 
cleavage of 30 amino acids from the amino terminus 
of PPARγ2 (55 KDa) produces the PPARγ1 isoform 
(50 KDa). Treatment of RAW264.7 cells with IL-4 
resulted in marked increase in immunoreactive 
material at 62/67 KDa suggesting that this higher 
molecular weight material reactive to the PPARγ 
antibody reflected a modified form of the primary 
translation product. 
Sumoylation is one of a limited number of 
posttranslational modifications that would increase 
apparent molecular weight of PPARγ by 11 to 12 
KDa (51). Sumoylation of PPARγ has been found to 
modulate its activity as a transcription factor (77,78), 
and sumoylation of PPARγ has been found 
specifically to mediate repression of pro-
inflammatory genes (79-81). We used siRNA 
technology to determine if immunoreactive material 
at 62/67 KDa contained a SUMO adduct. Transient 
transfection of RAW264.7 cells with antisense RNA 
to both the PIAS-1 conjugating enzyme and SUMO-1 
reduced immunoreactive material at 62/67 KDa that 
was induced in several ways, while antisense RNA to 
SUMO-2 did not affect this band (not shown). Levels 
of free SUMO-1 were likewise reduced by 
transfection with antisense RNA to SUMO-1. These 
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data indicate that the immunoreactive material at 
62/67 KDa obtained by reaction to antibody against 
PPARγ also contains a SUMO-1 adduct. We infer, 
therefore, that freshly isolated RAM from the rat 
express high levels of SUMO-PPARγ at 62/67KDa, 
and that the inflammatory MNP present in the lung 
following induction of inflammation express very 
low levels of SUMO-PPARγ. These observations 
support the argument that SUMO-PPARγ expressed 
in the RAM modulates the inflammatory state of 
these cells, whereas the newly recruited 
inflammatory MNP express very little SUMO-
PPARγ thereby contributing to their inflammatory 
state (79-81). 
Evidence that XOR was involved in PPARγ 
sumoylation was obtained in three ways. First, 
inhibitors of XOR, in the presence or absence of 
PMA, increased levels of SUMO-PPARγ at 62/67 
KDa in U937, HL-60, THP-1, and RAW264.7 cells. 
The increase in 62/67 KDa immunoreactive material 
was obtained with both Y-700 and oxypurinol, and 
similar results were obtained with allopurinol as well 
(data not shown). The consistent effect of the 
different inhibitors is important because the 
inhibitors have either different ROS scavenging 
properties (allopurinol and oxypurinol) that are 
distinct from inhibition of XOR per se and 
potentially confounding, or they have no detectable 
ROS scavenging properties (Y-700) (41). Second, 
ectopic overexpression of XOR cDNA dose 
dependently reduced levels of IL-4 induced 62/67 
KDa SUMO-PPARγ. Third, uric acid, the principle 
catalytic product of XOR dose dependently reduced 
levels 62/67 KDa SUMO-PPARγ that were produced 
either by IL-4 stimulation of RAW264.7 cells or by 
treatment of U937 cells with Y-700 and PMA. In 
aggregate, these data demonstrate that XOR 
modulates levels of SUMO-PPARγ immunoreactive 
material at 62/67 KDa, and identify uric acid as an 
important component of this effect. 
Modulation of PPARγ sumoylation explicitly 
predicts an inhibitory effect on Arginase-1 which is a 
canonical marker of alternatively activated (M2) 
macrophages that is specifically induced by IL-4 
(36). We observed IL-4 dose dependent increases in 
Arginase-1 levels that were reduced by antisense 
RNA to both SUMO-1 and PIAS-1 using RAW264.7 
cells, consistent with reports demonstrating the 
requirement of SUMO for PPARγ activation and 
PPARγ activation for induction of Arginase-1 
(36,55,68,77). Ectopic overexpression of XOR 
cDNA dose-dependently blocked IL-4 induced 
Arginase-1. Furthermore, both uric acid and oxonic 
acid, a uric acid elevating reagent, dose dependently 
reduced Arginase-1 levels that were induced with IL-
4. Furthermore, we also observed decreases in the 
M2 markers CD36 and CD206 by both oxonic acid 
and uric acid. These data confirm the involvement of 
XOR and uric acid in modulating markers of M2 
polarized RAW264.7 cells. 
The signaling pathways through which XOR 
activity modulates PPARγ sumoylation are unknown. 
XOR is an efficient source of both reactive oxygen 
and reactive nitrogen species, and both oxidative and 
nitrosative stress can regulate sumoylation (82-84). 
However, data shown here demonstrate that uric acid 
is at least one component of XOR biochemistry that 
modulates PPARγ sumoylation. XOR derived uric 
acid may exert proinflammatory effects at several 
levels. On the one hand, uric acid can activate the 
inflammasome to promote inflammation (59,85), 
promote T cell activation (86), activate dendritic cells 
(87), and as shown here modulate PPARγ 
sumoylation. Importantly, as shown here, these 
effects can arise at physiological levels of uric acid 
that are well below the point of crystallization and 
may therefore be distinct from the response to 
monosodium urate crystals (88). Uric acid can also 
serve as a scavenger of ROS, and this too may 
underlie its effects on PPARγ sumoylation and 
inflammation (37). 
HIF-1α plays an essential role in the 
development of inflammation as a product of the 
MNP (89-91), and MNP HIF-1α is required for the 
expression of inflammatory cytokines in an LPS 
model of sepsis (90).  Recent reports demonstrate 
that HIF-1α is also regulated by sumoylation. SUMO 
conjugation to HIF-1α both stabilizes the protein and 
reduces its activation function in transcription 
(56,57,92). Evidence that XOR is involved in 
regulating levels of HIF-1α protein was obtained 
using both I-MNP freshly isolated from Th-1 
cytokine insufflated rat lungs and U937 cells. In the 
presence of the proteosome inhibitor MIG132, XOR 
inhibitors increased both normoxic and hypoxic 
levels of HIF-1α and increased the levels of HIF-1α 
induced by treatment with LPS, IL-1, or IFNγ. 
Again, the use of three different inhibitors of XOR 
suggests that the effect on HIF-1α protein levels is 
the result of XOR inhibition per se. We infer that in 
the uninhibited MNP XOR activity modulates levels 
of HIF-1α protein. Experiments are currently 
underway to determine whether the effect of XOR on 
HIF-1α protein levels reflects the effect of XOR on 
sumoylation of HIF-1α. However, consistent with 
this observation, we observed marked decrease in 
VEGF, a principal target of HIF-1 regulation, in the 
presence of MIG132 at 6 and 24 hrs after exposure, 
when HIF-1α levels were most increased. 
Furthermore, inhibition of XOR in the absence of 
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MIG132 alone reduced VEGF secretion from these 
cells.  
Repair and rescue of the injured alveolar 
epithelium is a critical therapeutic objective for 
management of lung inflammatory disorders (93). 
While the relatively poor understanding of repair and 
injury has limited current treatment strategies, MNP 
are of considerable interest as therapeutic targets 
because they contribute to both injury and repair. 
During inflammation classically activated (M1) 
inflammatory MNP contribute to lung injury and 
PMN recruitment. On the other hand, alternatively 
activated (M2) MNP exhibit anti-inflammatory 
properties that may contribute to tissue repair. 
Experiments shown here demonstrate that XOR 
promotes the inflammatory state of MNP through 
effects on chemokine expression, PPARγ 
sumoylation, and HIF-1α, and that inhibitors of XOR 
reduce the inflammatory state. Thus, strategies that 
inhibit XOR may be important considerations for 
modulating lung inflammatory disorders. 
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FIGURE LEGENDS 
 
Figure 1. Inflammatory MNP express high levels of XOR activity. A, Circulating monocytes (CM and 
resident alveolar macrophages (RAM) were purified from control untreated rats while alveolar MNP (A-MNP) 
and interstitial MNP (I-MNP) were purified from rat lungs 24 hrs after insufflation of the Th-1 cytokines, IL-1β 
and INFγ. XOR activity was determined from six preparations of each. Data show the mean and standard 
deviation of XOR activity. Oxypurinol (150 uM) was included in separate assays to confirm the specificity of 
uric acid formation. B, RAM were purified from control untreated rats and placed into 12 well culture plates. 
After one hour cells were washed and either harvested immediately (Control, 0 hr) or exposed to vehicle, IL-1β 
(10 ng/ml), IFNγ (20 ng/ml), or LPS (1.0 ug/ml) in heat inactivated medium. Cells were harvested 24 hrs later 
and XOR activity determined. Data show the mean and standard deviation for six determinations.  C, NR8383 
rat AM cell line was cultured in 12 well plates at 1.0 x 106 cells/well and treated with vehicle, IL-1β (10 
ng/ml), IFNγ (20 ng/ml), or LPS (1.0 ug/ml) as in panel B. Cells were harvested 24 hrs later and XOR activity 
determined. Data show the mean and standard deviation for six determinations.   
 
Figure 2. XOR activity is increased in U937 cells by differentiation along the macrophage pathway and 
by the MCP-1 chemokine. A, U937 cells were cultured in 12 well plates at 1.0 x 106 cells/well and treated 
with PMA (30 nM), Vitamin D3 (1 × 10 7 M)/TGFβ1 (1 ng/ml), ATRA (1 x 10-6M), or MCP-1 (10 ng/ml) as 
shown. Cells were harvested and XOR activity determined 48 hrs after addition of each differentiation agent. 
Data show the mean and standard deviation of six determinations.   B, U937 cells were grown as in panel A 
and treated with increasing dose of PMA. Cells were harvested and XOR activity determined 48hrs later. Data 
show the mean and standard deviation of six determinations. In addition, U937 cells were grown as in panel A 
and treated with PMA (30 nM) for the indicated times. Cells were harvested and XOR activity determined on 
freshly generated WCE. Data show the mean and standard deviation of six determinations. C, U937 cells were 
grown as in panel A and treated with increasing dose of MCP-1. Cells were harvested and XOR activity 
determined 48 hrs later. Data show the mean and standard deviation of six determinations. In addition, U937 
cells were grown as in panel A and treated with MCP-1 (10 ng/ml) for the indicated times. Cells were 
harvested and XOR activity determined on freshly generated WCE. Data show the mean and standard deviation 
of six determinations. 
 
Figure 3. Allopurinol reduces secretion of CINC-1 but not MCP-1 or IL-10 from inflammatory MNP. A, 
Rats were insufflated with either saline (Sham) or Th-1 cytokines (IL-1/IFN) and five hours later the cell free 
lung lavage and serum were collected and levels of CINC-1 and MCP-1 were measured by ELISA. *** p<0.02, 
** p<0.05 using Students t-Test with n = six rats in each group.  B, I-MNP were purified from rats insufflated 
with Th-1 cytokines 24 hrs before and cultured in vitro in the presence or absence of LPS at 1.0 ug/ml. Levels 
of secreted CINC-1, MCP-1, and IL-10 were measured over a period of 48 hrs from the time LPS added to the 
cells. C, D, I-MNP from Th-1 cytokine insufflated rats were purified and were either untreated (C) or treated 
with LPS (D) as in Panel B, but were incubated in the presence or absence of allopurinol or oxypurinol (150 
uM). Levels of CINC-1, MCP-1, and IL-10 were determined 24 hrs later. ** p<0.05 using Students t-Test with 
n = three rats in each group. 
 
Figure 4.  PPARγ is expressed in rat lung MNP and cultured myeloid lineage cells. A, Western 
immunoblot of PPARγ from RAM of untreated control rats and from A-MNP and I-MNP purified from lungs 
of rats treated with Th-1 cytokines 24 hrs before. B, Western immunoblot of PPARγ from cultured myeloid 
lineage cells. Cells were either grown in the absence of PMA (30 uM) or treated with PMA for 24 or 48 hrs. C, 
Western immunoblot of PPARγ from RAW264.7 cells that were either treated with recombinant IL-4 (10 
ng/ml) or saline for 24 hrs. 
 
Figure 5. Anti-PPARγ immunoreactive material at 62/67 KDa contains a SUMO-1 adduct.  A, RAW264.7 
cells were plated at 0.5 x 106 cells/well on 12 well plates and the next day transfected with scrambled siRNA, 
anti-SUMO-1 siRNA, or siRNA for the PIAS SUMO-1 conjugating enzyme. After 24 hrs, cells were treated 
with either IL-4 (10 ng/ml), PMA and oxypurinol, or PMA and Y-700 (50 nM) as described in Figure 6. 
Western immunoblots were performed on WCE 24 hrs after treatment using antibodies to PPARγ. B, U937 
cells were plated at 0.5 x 106 cells/well on 12 well plates and the next day were either left untreated (control no 
siRNA) or transfected with anti-SUMO-1 siRNA(siRNA SUMO-1), or nonspecific DNA (siRNA reagent 
control). After 24 hrs, cells were treated with PMA and oxypurinol and western immunoblots were performed 
on WCE 24 hrs after treatment using antibodies to PPARγ or SUMO-1. C, Bands at 62/67 KDa were 
quantitated by scanning dosimetry and then averaged over all treatments (IL-4, Oxy/PMA, and Y-700/PMA). 
Data were normalized to the untreated control samples and shown as % of the control band.  Data show the 
normalized average and standard deviation for six determinations in each treatment group. ** p< 0.05, *** 
p<0.01 by Students t-test comparing Anti-SUMO-1 or Anti-PIAS to Scramble siRNA transfection.    
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Figure 6.  XOR inhibitors increase levels of SUMO-PPARγ in cultured myeloid lineage cell lines. U937, 
THP-1, HL-60, and RAW264.7 cells were plated in 12 well plates at 1 x 106 cells/well and grown under 
normoxic conditions for one hour. Subsequently, cells were treated with Y-700 (50 nM) or oxypurinol (150 
uM) for one hour and PMA (30 nM) was then added. Whole cell lysates were prepared 24 hrs or 48 hrs after 
exposure to PMA and western immunoblots were run sequentially with antibody to PPARγ and GAPDH. 
Representative blots are shown of three independent blots for each experiment.   
 
Figure 7.  Ectopic overexpression of XOR or uric acid supplementation both reduce levels of SUMO-
PPARγ in cultured myeloid lineage cell lines. A, RAW264.7 cells were plated in 6 well plates at 0.5 x 106 
cells/well and the next day were transfected with the indicated doses of pCMV-Myc-XOR. After 24 hrs, cells 
were shifted into standard medium with charcoal stripped and heat inactivated FBS and treated with 
recombinant mouse IL-4 (10 ng/ml). Whole cell lysates were prepared 24 hrs after exposure to IL-4 and 
western immunoblots were run sequentially with antibody to PPARγ and GAPDH. Representative blots are 
shown of three independent blots for each experiment.  B, RAW264.7 cells were plated in 6 well plates at 1.0 x 
106 cells/well. The next day cells were shifted into standard medium with charcoal stripped and heat inactivated 
FBS and treated with uric acid at the indicated doses in the presence of 50 mM oxonic acid. After one hour 
cells were treated with 10 ng/ml of IL-4. Cells were harvested 24 hours later, lysates prepared, and western 
immunoblots performed sequentially against PPARγ and GAPDH.  C, U9376 cells were plated at a density of 1 
x106 cells/well in six well plates. Cells were then treated with uric acid at the indicated doses and after one hour 
were exposed to PMA and Y-700 exactly as described in Figure 6. Cell lysates were prepared after 24 hrs and 
western immunoblots were performed sequentially against PPAR γ and GAPDH.  
 
Figure 8. Levels of the M2 markers Arginase-1, CD36, and CD206 are reduced by uric acid or oxonic 
acid. A, RAW264.7 cells were plated at 0.5 x106 cells/well and the next day treated with recombinant mouse 
IL-4 from 0 to 20 ng/ml. WCE were prepared 24 hrs later and western blots performed with antisera to 
Arginase-1.  B, RAW264.6 cells were plated as in panel A and the next day were either left untreated or were 
transfected with scrambled siRNA, anti-sumo-1 siRNA, or anti-PIAS siRNA. After 24 hrs cells were treated 
with IL-4 and 24 hrs later WCE prepared. Western immunoblots were performed using antisera to PPARγ, 
Arginase-1, or GAPDH. C, RAW264.6 cells were plated as in panel A and the next day were either left 
untreated or were transfected with pCMV-Myc vector alone or with pCMV-Myc-XOR in the presence of 
pCMV-Myc to fix the net input DNA at 3.0ug. After 24 hrs cells were treated with IL-4 and 24 hrs later WCE 
prepared. Western immunoblots were performed using antisera to Arginase-1 or GAPDH. Arginase-1 bands 
were quantitated by scanning dosimetry and normalized to the untransfected cells treated with IL-4. D, 
RAW264.7 cells were plated as in panel A and the next day treated with oxonic acid at the indicated doses. 
After one hour cells were treated with IL-4 and WCE prepared 24 hrs later. Western immunoblots were 
performed using antisera to Arginase-1 and GAPDH. E, RAW264.7 cells were plated as in panel A and the 
next day treated with uric acid at the indicated doses in the presence of oxonic acid (50 uM). After one hour 
cells were treated with IL-4 and WCE prepared 24 hrs later. Western immunoblots were performed using 
antisera to Arginase-1 and GAPDH. F, RAW264.7 cells were plated as in Panel A, shifted into charcoal 
stripped/heat inactivated medium, and treated with the indicated doses of oxonic acid alone or in combination 
with uric acid at the indicated doses. One hour later cells were treated with 10 ng/ml IL-4. Cells were harvested 
24 hrs after treatment and analyzed by flow cytometry using antibodies to CD36 (PE conjugated) and CD206 
(FITC conjugated). 
 
Figure 9. Inhibition of XOR activity increases levels of HIF-1α protein in rat inflammatory MNP and in 
PMA differentiated U937 cells. A, I-MNP were purified from rat lungs 24 hrs following insufflation of Th-1 
cytokines and were plated in 12 well plates at 1.0 x 106 cells/well and grown under normoxic conditions. 
Nonadherent cells removed by washing after one hour and cells were treated with the indicated doses of 
MIG132. Cells were harvested after 6 hrs, whole cell lysates prepared, and western immunoblots run with 
antibody to HIF-1α. In addition, washed, adherent cells were exposed to MIG132 (50 uM) for the indicated 
times, and western immunoblots were run on whole cell lysates and probed with antibody to HIF-1α. Blots 
were subsequently stripped and re-probed with antibody to GAPDH to control for protein loading.  B, I-MNP 
were purified and plated as in panel A. Plates were placed in either normoxic (21% O2, 5% CO2) or hypoxic 
culture (1% O2, 5% CO2, 94% N). After one hour cells were treated with the XOR inhibitors allopurinol 
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(150uM), oxypurinol (150uM), or Y-700 (50 nM). One hour later cells were treated with MIG132 (50uM) and 
grown for 6 hrs. Whole cell lysates were then prepared and western immunoblots run with independent 
duplicate samples as indicated. Blots were first probed with antibody to HIF-1α and subsequently with 
antibody to GAPDH.  Bands from western immunoblots were quantitated by scanning dosimetry and 
normalized to the signal obtained from the GAPDH blots. Data show the mean and standard deviation of 
duplicate samples. C, I-MNP were purified, plated, and grown in normoxia in the presence of MIG132 as in 
panel A. Cells were exposed to the XOR inhibitor Y-700 (50 nM) for one hour and subsequently treated with 
IL-1β (10 ng/ml), IFNγ (20 ng/ml), or LPS (1.0 ug/ml). Whole cell lysates were prepared and western 
immunoblots run after 24 hrs exposure to cytokines. Blots were run on triplicate samples and representative 
blots are shown. Bands from western immunoblots were quantitated by scanning dosimetry and normalized to 
the signal obtained from the GAPDH blots. Data show the mean and standard deviation of triplicate blots.  D, 
U937 cells were plated in 12 well plates at 1 x 106 cells/well and treated with PMA (30 nM) for 48 hrs. Cells 
were then washed, the medium replaced, and cells were grown under normoxic or hypoxic conditions for one 
hour in the presence of 50 uM MIG132. Subsequently, cells were treated with Y-700 (50 nM) for one hour and 
cytokines added as above. Whole cell lysates were prepared after 24 hrs exposure to cytokine/MIG132 and 
western immunoblots run sequentially with antibody to HIF-1α and GAPDH. Representative blots are shown 
of three independent blots for each experiment. Bands from western immunoblots were quantitated by scanning 
dosimetry and normalized to the signal obtained from the GAPDH blots. Data show the mean and standard 
deviation of triplicate blots. E, I-MNP were purified and plated in normoxia as in panel B. Levels of VEGF 
were quantitated in the cell free supernatant over a period of 48 hrs in culture. In addition, cells were treated 
independently with MIG132 in the absence or presence of allopurinol, oxypurinol, or Y-700 as in panel B, and 
levels of VEGF were measured in the cell free supernatant 6 or 24 hrs after treatment. Data show the mean and 
standard deviation of three independent experiments. F, I-MNP were plated as above in the presence or absence 
of Y-700 (1.0 mM) and in the absence of MIG132. After 24 hrs cell free supernatants were collected and 
analyzed with the rat specific Proteome Profiler. Experiments were performed in quadruplicate and each 
cytokine was analyzed from two spots on each filter (boxed for VEGF), thus all data reflect 8 independent 
determinations for VEGF alone. Spots were quantitated as described by the supplier using an R&D 
transmission mode scanner and image analysis software from R & D. Data show the mean and standard 
deviation of light transmission signals (arbitrary units) from 8 spots for VEGF only and both Control and Y-
700 groups and were normalized first to the mean positive control spots (A1, A2, A19, A20, D1, D2) and 
subsequently to the signal obtained from the Control samples which was thereby set at 1.00. 
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TABLES 
 
Table 1. XOR activity in RAM and NR8383 cells treated with Th-1 cytokines as described in the 
legend to Fig. 1.  
 
 Control IL-1β IFNγ IL-1β/ IFNγ LPS 
RAM 0.0794 0.238 0.695 0.596 0.488 
  (p<0.01) (p<0.01) (p<0.01) (p<0.01) 
NR8383 0.252 0.366 0.781 0.922 0.694 
  (p<0.05) (p<0.02) (p<0.01) (p<0.02) 
 
 
 
